You are here

Home » Content

Türk Tüberküloz Hastalarında İnterferon Gamma (IFN-g) Promoter ve P2X7 Polimorfizimleri

Interferon Gamma (IFN-γ) Promoter and P2X7 Polymorphisms in Turkish Tuberculosis Patients

Journal Name:

  • Akdeniz Tıp Dergisi

Publication Year:

  • 2016
DOI: 
10.17954/amj.2016.57

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Almost one-third of the world population has been infected with the tuberculosis (TB) bacillus, but TB develops only in 5-10% of the infected people. IFN-γ (interferon gamma) is the most important cytokine that plays a role in resistance to TB. There are many studies demonstrating that a single nucleotide polymorphisms in the “Purinergic Receptor” (P2X7) and promoter site of the IFN-γ genes may cause susceptibility to TB. To our knowledge, there is no study associated with the effects of these polymorphisms in the Turkish population. In this study, the relationship between -155A/G and -183G/T polymorphisms in the interferon gamma gene and susceptibility to TB disease were investigated in a case-control study. Also, the A1513C polymorphism that usually occurs in the P2X7 gene was examined in the same study. In conclusion, the -155A/G and -183G/T polymorphisms of the IFN-γ gene were not found in the TB patients and in the control groups. This outcome suggests us that these polymorphisms may barely appear in the Turkish population. However, although the P2X7 A1513C polymorphism that changes glutamine to alanine at codon 496 was detected in both groups, there was no significant relationship between the occurrence of this polymorphism and resistance/or susceptibility to TB (AC; p=0.145 OR=1.521) (CC; p=0.851 OR=1.114) (AA; p=0.171 OR=1.447). Our findings suggest that TB susceptibility genes may differ in different populations.
Bookmark/Search this post with
Abstract (Original Language): 
Dünya nüfusunun 1/3’ ü tüberküloz (TB) basili ile infektedir, fakat tüberküloz hastalığı bu bireylerin sadece % 5-10’ unda gelişmektedir. IFN-γ, TB hastalığına dirençte en önemli sitokindir. TB hastalığına yatkınlıkta “Purinergic Receptor” (P2X7) ve IFNγ genlerindeki tek nükleotid değişimlerinin etkili olduğunu gösteren birçok yayın vardır. Araştırmalarımıza göre Türk toplumunda bu polimorfizmlerin etkisi ile ilişkili hiç çalışma yoktur. Bu projede biz TB hastalığına dirençte interferon gamma geni -155A/G ve -183G/T polimorfizmlerinin ilişkisini bir olgu - kontrol araştırması ile incelemeyi planladık. Aynı zamanda P2X7 geninde genellikle görülen A1513C polimorfizminide çalışmamızda araştırdık. Sonuçta TB hastalığında ve kontrol gruplarında IFNγ -155A/G ve -183G/T polimorfizmleri ile ilgili herhangi bir bulguya rastlanmadı. Bu sonuçlar bize bu polimorfizmin Türk toplumunda nadir olarak rastlanabileceğini gösteriyor. Bununla birlikte P2X7 genindeki Glu496Ala değişimine sebep olan A1513C polimorfizmi her iki grupta da belirlenmesine rağmen TB hastalığına yatkınlık ve dirençte bu hastalıkların görülmesi arasında anlamlı bir ilişki yoktur. (AC; p=0,145 OR=1,521) (CC; p=0,851 OR=1,114) (AA; p=0,171 OR=1,447). Bu bulgular da gösteriyor ki TB hastalığına yatkınlık genleri popülasyonlara göre farklılık gösterebilir.
FULL TEXT (PDF): 
PDF icon arastirmax-turk-tuberkuloz-hastalarinda-interferon-gamma-ifn-g-promoter-p2x7-polimorfizimleri.pdf
  • 3
133
141
  • Turkish

REFERENCES

References: 

1. Deligezer U, Akışık EE, Dalay N. The Application of the
light cycler Fluorescence PCR in polymorphism analysis:
Investigation of the Mthfr C677T Polymorphism in
childhood and adult patients with Myeloid Leukemia.
Türk Onkoloji Dergisi 2004; 19:134-9.
2. Casanova JL, Abel L. Genetic dissection of immunity to
mycobacteria: The human model. Annu Rev Immunol
2002; 20:581-620.
3. Cooke GS, Hill AV. Genetics of susceptibility to human
infectious disease. Nat Rev Genet 2001; 2:967-77.
4. Barnes PF, Cave MD. Molecular epidemiology of
tuberculosis. N Engl J Med 2003; 349:1149-56.
5. Narayanan S. Molecular epidemiology of tuberculosis.
Indian J Med Res 2004; 120:233-47.
6. Feng CG, Kaviratne M, Rothfuchs AG, Cheever A, Hieny
S, Young HA, Wynn TA, Sher A. NK cell-derived IFNgamma
differentially regulates innate resistance and
neutrophil response in T cell-deficient hosts infected with
Mycobacterium tuberculosis. J Immunol 2006; 177: 7086-
93.
7. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev
Immunol 2001; 19:93-129.
8. Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse
E. Control of human host immunity to mycobacteria.
Tuberculosis (Edinb) 2005; 85: 53-64.
9. van Crevel R, Ottenhoff TH, van der Meer JW. Innate
immunity to Mycobacterium tuberculosis. Clin Microbiol
Rev 2002; 15:294-309.
10. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferongamma:
An overview of signals, mechanisms and
functions. J Leukoc Biol 2004; 75:163-89.
11. North RA. Molecular physiology of P2X receptors.
Physiol Rev 2002; 82:1013-67.
12. Jacobson KA, Jarvis MF, Williams M. Purine and
pyrimidine (P2) receptors as drug targets. J Med Chem
2002; 45:4057-93.
13. Surprenant A, Rassendren F, Kawashima E, North RA,
Buell G. The cytolytic P2Z receptor for extracellular ATP
identified as a P2X receptor (P2X7). Science 1996; 272:
735-8.
140
Konuk E et al.
Akd Tıp D / Akd Med J / 2016; 3: 133-141
14. Berrington WR, Hawn TR. Mycobacterium tuberculosis,
macrophages, and the innate immune response: Does
common variation matter? Immunol Rev 2007; 219:167-
86.
15. Fernando SL, Saunders BM, Sluyter R, Skarratt KK,
Wiley JS, Britton WJ. Gene dosage determines the negative
effects of polymorphic alleles of the P2X7 receptor on
adenosine triphosphate-mediated killing of mycobacteria
by human macrophages. J Infect Dis 2005; 192:149-55.
16. Shemon AN, Sluyter R, Fernando SL, Clarke AL, Dao-
Ung LP, Skarratt KK, Saunders BM, Tan KS, Gu BJ,
Fuller SJ, Britton WJ, Petrou S, Wiley JS. A Thr357
to Ser polymorphism in homozygous and compound
heterozygous subjects causes absent or reduced P2X7
function and impairs ATP-induced mycobacterial killing
by macrophages. J Biol Chem 2006; 281:2079-86.
17. Li CM, Campbell SJ, Kumararatne DS, Bellamy R,
Ruwende C, McAdam KP, Hill AV, Lammas DA.
Association of a polymorphism in the P2X7 gene with
tuberculosis in a Gambian population. J Infect Dis 2002;
186:1458-62.
18. Fernando SL, Saunders BM, Sluyter R, Skarratt KK,
Goldberg H, Marks GB, Wiley JS, Britton WJ. A
polymorphism in the P2X7 gene increases susceptibility
to extrapulmonary tuberculosis. Am J Respir Crit Care
Med 2007; 175: 360-6.
19. Saunders BM, Fernando SL, Sluyter R, Britton WJ, Wiley
JS. A loss-of-function polymorphism in the human P2X7
receptor abolishes ATP-mediated killing of mycobacteria.
J Immunol 2003; 171:5442-6.
20. Organization WH. Global tuberculosis control. WHO
report Geneva, Switzerland, 1999; WHO/CDS/CPS/
TB 99.259. http://www.who.int/en/
21. Gaudelus J, De Pontual L. Epidemiology of tuberculosis
in France. Arch Podiatry 2005; 12:83-7.
22. Kochi A. Tuberculosis: distribution, risck factors, mortality.
Immunobiology 1994; 191:325-36.
23. Rassendren F, Buell GN, Virginio C, Collo G, North RA,
Surprenant A. The permeabilizing ATP receptor, P2X7.
Cloning and expression of a human cDNA. J Biol Chem
1997; 272:5482-6.
24. Gu BJ, Zhang W, Worthington RA, Sluyter R, Dao-
Ung P, Petrou S, Barden JA, Wiley JS. A Glu-496 to Ala
polymorphism leads to loss of function of the human
P2X7 receptor. J Biol Chem 2001; 276:11135-42.
25. Wiley JS, Gargett CE, Zhang W, Snook MB, Jamieson
GP. Partial agonists and antagonists reveal a second
permeability state of human lymphocyte P2Z/P2X7
channel. Am J Physiol 1998; 275:C1224-31.
26. Humphreys BD, Rice J, Kertesy SB, Dubyak GR. Stressactivated
protein kinase/JNK activation and apoptotic
induction by the macrophage P2X7 nucleotide receptor.
J Biol Chem 2000; 275:26792-8.
27. Boldt W, Klapperstuck M, Buttner C, Sadtler S, Schmalzing
G, Markwardt F. Glu496Ala polymorphism of human
P2X7 receptor does not affect its electrophysiological
phenotype. Am J Physiol Cell Physiol 2003; 284:C749-56.
28. Bream JH, Ping A, Zhang X, Winkler C, Young HA. A
single nucleotide polymorphism in the proximal IFNgamma
promoter alters control of gene transcription.
Genes Immun 2002; 3:165-9.
29. Chevillard C, Henri S, Stefani F, Parzy D, Dessein A. Two
new polymorphisms in the human interferon gamma
(IFN-gamma) promoter. Eur J Immunogenet 2002; 29:
53-6.
30. Sallakci N, Coskun M, Berber Z, Gurkan F, Kocamaz H,
Uysal G, Bhuju S, Yavuzer U, Singh M, Yegin O. Interferon-
gamma gene+874T-A polymorphism is associated
with tuberculosis and gamma interferon response. Tuberculosis
(Edinb) 2007; 87:225-30.
31. Qi S, Cao B, Jiang M, Xu C, Dai Y, Li K, Wang K, Ke Y,
Ning T. Association of the -183 polymorphism in the IFNgamma
gene promoter with hepatitis B virus infection in
the Chinese population. J Clin Lab Anal 2005; 19:276-81.
32. Sluyter R, Dalitz JG, Wiley JS. P2X7 receptor polymorphism
impairs extracellular adenosine 5’-triphosphateinduced
interleukin-18 release from human monocytes.
Genes Immun 2004; 5:588-91.
33. Sluyter R, Shemon AN, Wiley JS. Glu496 to Ala
polymorphism in the P2X7 receptor impairs ATPinduced
IL-1 beta release from human monocytes. J
Immunol 2004; 172:3399-405.
34. Georgiou JG, Skarratt KK, Fuller SJ, Martin CJ,
Christopherson RI, Wiley JS, Sluyter R. Human
epidermal and monocyte-derived langerhans cells express
functional P2X receptors. J Invest Dermatol 2005; 125:
482-90.
35. Sluyter R, Wiley JS. Extracellular adenosine 5’-triphosphate
induces a loss of CD23 from human dendritic cells
via activation of P2X7 receptors. Int Immunol 2002;
14:1415-21.
36. Gu BJ, Wiley JS. Rapid ATP-induced release of matrix
metalloproteinase 9 is mediated by the P2X7 receptor.
Blood 2006; 107:4946-53.
37. Bai J, Marks GB, Stewart GJ, Simpson SE, Sullivan EA.
Specificity of notification for tuberculosis among screened
refugees in NSW. Aust N Z J Public Health 1999; 23: 410-
3.
141
Interferon Gamma (IFN-γ) Promoter and P2X7 Polymorphisms in Turkish Tuberculosis Patients
Akd Tıp D / Akd Med J / 2016; 3: 133-141
38. Hoal-Van Helden EG, Epstein J, Victor TC, Hon D, Lewis
LA, Beyers N, Zurakowski D, Ezekowitz AB, Van Helden
PD. Mannose-binding protein B allele confers protection
against tuberculous meningitis. Pediatr Res 1999; 45:459-
64.
39. Kim JH, Lee SY, Lee SH, Sin C, Shim JJ, In KH, Yoo
SH, Kang KH. NRAMP1 genetic polymorphisms as a
risk factor of tuberculous pleurisy. Int J Tuberc Lung Dis
2003; 7:370-5.
40. Nino-Moreno P, Portales-Perez D, Hernandez-Castro
B, Portales-Cervantes L, Flores-Meraz V, Baranda
L, Gomez-Gomez A, Acuna-Alonzo V, Granados J,
Gonzalez-Amaro R. P2X7 and NRAMP1/SLC11 A1
gene polymorphisms in Mexican mestizo patients with
pulmonary tuberculosis. Clin Exp Immunol 2007; 148:
469-77.
41. Kusner DJ, Adams J. ATP-induced killing of virulent
Mycobacterium tuberculosis within human macrophages
requires phospholipase D. J Immunol 2000; 164:379-88.
42. Mokrousov I, Sapozhnikova N, Narvskaya O.
Mycobacterium tuberculosis co-existence with humans:
Making an imprint on the macrophage P2X(7) receptor
gene? J Med Microbiol 2008; 57:581-4.

Thank you for copying data from http://www.arastirmax.com